Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
VTSI VirTra Inc
ALHC Alignment Healthcare Inc
PRGS Progress Software Corp
PMD Psychemedics Corp
RPHM Reneo Pharmaceuticals Inc
DFSU Dimensional US Sustainability Core 1 ETF
UNH UnitedHealth Group Inc
GURE Gulf Resources Inc
TDCX TDCX Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Closing Price
$821.67
Day's Change
10.17 (1.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
822.52
Day's Low
810.95
Volume
(Above Average)
Volume:
866,170

10-day average volume:
765,078
866,170
Historical quotes & splits

Display:

Providers:

UpdateCancel
6 providers
Search
Any date
Any date
Last 24 hours
Last 7 days
April 2023
March 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
March 29, 2023
Libtayo(R) (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)(Globe Newswire)
March 28, 2023
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization...(BusinessWire)

Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases(Globe Newswire)
March 23, 2023
Thinking about trading options or stock in Regeneron Pharmaceuticals, NetEase, Netflix, Advanced Micro Devices, or Novo Nordisk?

InvestorsObserverissues critical PriceWatch Alerts for REGN, NTES, NFLX, AMD, and NVO. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

Press Release: Dupixent(R) demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial(Globe Newswire)
Dupixent(R) (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial(Globe Newswire)
March 22, 2023
FDA Approves First-in-class Evkeeza(R) (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol(Globe Newswire)
March 21, 2023
Press Release: Dupixent(R) (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis(Globe Newswire)
Dupixent(R) (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis(Globe Newswire)
March 18, 2023
Press Release: Dupixent(R) (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis(Globe Newswire)
Dupixent(R) (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis(Globe Newswire)
March 14, 2023
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

$250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors Regeneron Pharmaceuticals, Inc.and Society for Science(the Society) announced that Neel Moudgal, 17, of Saline...(PR Newswire)

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease(Globe Newswire)
March 07, 2023
Press Release: Dupixent(R) (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review(Globe Newswire)
Dupixent(R) (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review(Globe Newswire)
February 28, 2023
Kevzara(R) (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica(Globe Newswire)
February 24, 2023
Libtayo(R) (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)(Globe Newswire)
February 23, 2023
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review(Globe Newswire)
February 21, 2023
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review(Globe Newswire)
February 08, 2023
EYLEA(R) (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.

3rd Party Research Disclosure